Company Overview: OncoCyte

Industry News

27 Sep

OncoCyte Announces Successful Completion of CLIA Lab Validation Study of its DetermaVu™ Lung Cancer Diagnostic Test; Clinical Validation Study Initiated

ALAMEDA, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive, blood-based liquid biopsy tests to assist in the early detection of cancer, announced today that its CLIA laboratory has successfully completed a rigorous validation study of DetermaVu™, OncoCyte’s diagnostic test for lung cancer. In...

Read more

18 Sep

OncoCyte Reports Positive Analytical Validation Study Results of DetermaVu™ Lung Cancer Diagnostic Test

ALAMEDA, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests to assist in the early detection of cancer, announced today positive final results from the Analytical Validation Study of its liquid biopsy lung cancer diagnostic test, DetermaVU™. The data were...

Read more

7 Sep

OncoCyte Receives CLIA Certification for its Cancer Diagnostics Laboratory

ALAMEDA, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that its clinical laboratory facility located in Alameda, California, has received Clinical Laboratory Improvements Amendments (CLIA) certification of registration from the Centers for Medicare...

Read more

26 Jun

OncoCyte Corporation Added to Russell 3000® Index and Russell 2000® Index

ALAMEDA, Calif., June 26, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the early detection of cancer, has been added to the broad U.S. market Russell 3000® Index and the small-cap Russell 2000® Index as part of Russell Investments’...

Read more

29 Jan

OncoCyte

OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company believes that better and earlier detection of cancer through liquid biopsies will: Improve patient outcomes Increase the life expectancy of cancer patients Significantly reduce health care...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address